Hemorrhagic transformation of ischemic brain tissue -: Asymptomatic or symptomatic?

被引:467
作者
Berger, C
Fiorelli, M
Steiner, T
Schäbitz, WR
Bozzao, L
Bluhmki, E
Hacke, W
von Kummer, R
机构
[1] Univ Heidelberg, Dept Neurol, D-69221 Heidelberg, Germany
[2] Univ Dresden, Dept Neuroradiol, Dresden, Germany
[3] Univ Rome, Dept Neuroradiol, Rome, Italy
[4] Boehringer Ingelheim, Biberach, Germany
基金
中国国家自然科学基金;
关键词
hematoma; hemorrhagic stroke; stroke outcome; thrombolysis;
D O I
10.1161/01.STR.32.6.1330
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose - The term symptomatic hemorrhage secondary to ischemic stroke implies a clear causal relationship between clinical deterioration and hemorrhagic transformation (HT) regardless of the type of HT. The aim of this study was to assess which type of HT independently affects clinical outcome. Methods - We used the data set of the European Cooperative Acute Stroke Study (ECASS) II for a post hoc analysis, All patients had a control CT scan after 24 to 96 hours or earlier in case of rapid and severe clinical deterioration, HT was categorized according to radiological criteria: hemorrhagic infarction type 1 and type 2 and parenchymal hematoma type 1 and type 2, The clinical course was prospectively documented with the National Institutes of Health Stroke Scale and the modified Rankin Scale. The independent risk of each type of HT was calculated for clinical deterioration at 24 hours and disability and death at 3 months after stroke onset and adjusted for possible confounding factors such as age, severity of stroke syndrome at baseline, and extent of the ischemic lesion on the initial CT, Results - Compared with absence of HT, only parenchymal hematoma type 2 was associated with an increased risk for deterioration at 24 hours after stroke onset (adjusted odds ratio, 18; 95% CI, 6 to 56) and for death at 3 months (adjusted odds ratio, 11; 95% CI, 3.7 to 36), All other types of HT did not independently increase the risk of late deterioration. Conclusions - Only parenchymal hematoma type 2 independently causes clinical deterioration and impairs prognosis. It has a distinct radiological feature: it is a dense homogeneous hematoma > 30% of the ischemic lesion volume with significant space-occupying effect.
引用
收藏
页码:1330 / 1335
页数:6
相关论文
共 27 条
  • [1] ASPLUND K, 1985, STROKE, V16, P885
  • [2] Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy
    Barber, PA
    Demchuk, AM
    Zhang, JJ
    Buchan, AM
    [J]. LANCET, 2000, 355 (9216) : 1670 - 1674
  • [3] BOZZAO L, 1991, AM J NEURORADIOL, V12, P1115
  • [4] Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke
    Brott, T
    Broderick, J
    Kothari, R
    ODonoghue, M
    Barsan, W
    Tomsick, T
    Spilker, J
    Miller, R
    Sauerbeck, L
    Farrell, J
    Kelly, J
    Perkins, T
    Miller, R
    McDonald, T
    Rorick, M
    Hickey, C
    Armitage, J
    Perry, C
    Thalinger, K
    Rhude, R
    Schill, J
    Becker, PS
    Heath, RS
    Adams, D
    Reed, R
    Klei, M
    Hughes, A
    Anthony, J
    Baudendistel, D
    Zadicoff, C
    Rymer, M
    Bettinger, I
    Laubinger, P
    Schmerler, M
    Meiros, G
    Lyden, P
    Dunford, J
    Zivin, J
    Rapp, K
    Babcock, T
    Daum, P
    Persona, D
    Brody, M
    Jackson, C
    Lewis, S
    Liss, J
    Mahdavi, Z
    Rothrock, J
    Tom, T
    Zweifler, R
    [J]. STROKE, 1997, 28 (11) : 2109 - 2118
  • [5] URGENT THERAPY FOR STROKE .1. PILOT-STUDY OF TISSUE PLASMINOGEN-ACTIVATOR ADMINISTERED WITHIN 90 MINUTES
    BROTT, TG
    HALEY, EC
    LEVY, DE
    BARSAN, W
    BRODERICK, J
    SHEPPARD, GL
    SPILKER, J
    KONGABLE, GL
    MASSEY, S
    REED, R
    MARLER, JR
    [J]. STROKE, 1992, 23 (05) : 632 - 640
  • [6] Effectiveness of t-PA in acute ischemic stroke - Outcome relates to appropriateness
    Buchan, AM
    Barber, PA
    Newcommon, N
    Karbalai, HG
    Demchuk, AM
    Hoyte, KM
    Klein, GM
    Feasby, TE
    [J]. NEUROLOGY, 2000, 54 (03) : 679 - 684
  • [7] CANDELISE L, 1995, LANCET, V346, P1509
  • [8] Intravenous tissue plasminogen activator for acute ischemic stroke: Feasibility, safety, and efficacy in the first year of clinical practice
    Chiu, D
    Krieger, D
    Villar-Cordova, C
    Kasner, SE
    Morgenstern, B
    Bratina, PL
    Yatsu, FM
    Grotta, JC
    [J]. STROKE, 1998, 29 (01) : 303 - 303
  • [9] Ischaemic damage of brain microvessels: inherent risks for thrombolytic treatment in stroke
    del Zoppo, GJ
    Von Kummer, R
    Hamann, GF
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1998, 65 (01) : 1 - 9
  • [10] Streptokinase for acute ischemic stroke with relationship to time of administration
    Donnan, GA
    Davis, SM
    Chambers, BR
    Gates, PC
    Hankey, GJ
    McNeil, JJ
    Rosen, D
    StewartWynne, EG
    Tuck, RR
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (12): : 961 - 966